Other substances

Vistusertib

A mammalian target of rapamycin inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

2
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Vistusertib is a mammalian target of rapamycin complex 1 (mTORC1) inhibitor with potential antineoplastic activity. It was suggested to inhibit SARS-CoV-2 infection via mTORC1 inhibition (although by an unknown mechanism) (Mullen et al., 2021; NCIt).

Vistusertib on DrugBank
Vistusertib on PubChem

Synonyms

AZD2014

 

Structure image - Vistusertib

C[C@H]1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=CC=C4)C(=O)NC)N5CCOC[C@@H]5C

Supporting references

Link Tested on Impact factor Notes Publication date
SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibition
Small molecule In vitro 		Vero cells; human lung air-liquid interface cultures; SARS-CoV-2 isolate USA-WA1/2020 12.12

Inhibited SARS-CoV-2 replication in Vero cells, possibly through mTORC1 inhibition.

 Mar/25/2021
Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication
Small molecule In vitro Mechanism 		Vero E6 cells; Calu-3 cells; HEK293-ACE2 cells; HeLa-ACE2 cells; A549-ACE2 cells; human-induced pluripotent stem-cell-derived cardiomyocyte; SARS-CoV-2 isolate USA-WA1/2020 8.11

Inhibited SARS-CoV-2 infection in Vero E6 cells. It displayed some cytotoxicity, however.

 Mar/17/2021
Export (.csv)